The 5th China Healthcare Investment Conference (CHIC) was held on March 4-6, 2014 in Shanghai. Dr. Zhenkun Ma, Founder and CEO of TenNor Therapeutics, was invited to speak at the conference and share TenNor’s product portfolio and development strategy. First held in 2010, CHIC was a joint effort by a group of world-class investors who had recognized that the healthcare reform and economic growth in China were spurring a new wave of emerging Chinese healthcare companies. Now in its 5th year, CHIC has established itself as the preeminent platform to promote and nurture the Chinese healthcare investment ecosystem and further develop the biotechnology industry.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of January 24, 2026, TenNor Therapeutics had built a pipeline of seven innovative programs, including two Core Products, namely, rifasutenizol (TNP-2198), a new molecular entity (“NME”) drug candidate used as part of a triple therapy in combination with amoxicillin and a proton pump inhibitor for the treatment of Helicobacter pylori (“H. pylori”) infection in China and U.S. as well as monotherapy for bacterial vaginosis and C. difficile infection in China; and rifaquizinone (TNP-2092 injection), a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections, i.e. acute bacterial skin and skin structure infection (“ABSSSI”) and prosthetic joint infection (“PJI”), as well as left ventricular assist device infection (“LVADI”) and catheter-related bloodstream infection (“CRBSI”) in China and the U.S.

For more information, please visit: www.tennortherapeutics.com